| Autor: |
Akhter, Javed, Chen, Xianghai, Bowrey, Patricia, Bolton, Elaine J., Morris, David L. |
| Zdroj: |
Diseases of the Colon & Rectum; Mar1997, Vol. 40 Issue 3, p317-321, 5p |
| Abstrakt: |
In this study, we investigated the effect of the vitamin D3 analog, EB1089, on the growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model.BALB/c Nu/Nu nude mice were inoculated subcutaneously with 106 LoVo cells. EB1089 dissolved in isopropanol was administered intraperitoneally and orally on alternate days at doses of 0.1, 0.5, and 2.5 μ g/kg/day. Control animals received isopropanol alone. Tumor volumes estimated using the formula 0.5×length×(width). The tumor kinetic index was determined by immunohistochemical detection of proliferating cell nuclear antigen.Significant dose-dependent inhibition of tumor growth was seen. After 20 days of treatment with 0.1 μ g/kg/day EB1089, mean tumor volume in treated mice was 41 to 49 percent less than that in control animals (P <0.01). Significant inhibition of tumor growth was also seen with 0.5 μ g/kg/day EB1089 after 22 days of treatment (51 percent of control P <0.01). Treatment with 2.5 μ g/kg/day resulted in weight loss that required termination of this group; these mice were subsequently found to be hypercalcemic. The tumor kinetic index was significantly lower in tumors treated with 0.1 μ g/kg/day EB1089 compared with that for control tumors (8 vs. 30 percent in controls).These findings suggest that the vitamin D3 analog, EB1089, is a potent antiproliferative agent for some human colon cancers. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink